Neurally mediated @entity1163 is a complex syndrome that is often difficult to manage using currently available treatment strategies. The efficacy and safety of @entity2053 was evaluated in 35 @entity1 with @entity1274 mediated @entity1163 . All @entity1 had @entity1163 (n = 33) or disabling @entity1163 (n = 2) and a positive @entity135 ( @entity135 ) despite treatment with one or more of the following therapies: beta-blocker, high-salt diet, @entity7842 , elastic compression stockings, and @entity7306 . @entity2053 was initiated at 0.5 mg/day and titrated in 0.25-0.5 mg/day increments for symptom control. Early (first 8 weeks) symptomatic response was achieved in 31 of 35 (89%) @entity1 . Early @entity135 reverted to negative in 29 of 35 (83%) @entity1 . Two @entity1 discontinued @entity2053 during early follow-up due to side effects. Thirty-three @entity1 received long-term @entity2053 therapy. Twenty-five @entity1 had late @entity135 with 21 remaining negative. Of the eight @entity1 who did not have late @entity135 , one @entity1 discontinued @entity2053 prior to @entity135 due to side effects. Seven @entity1 refused late @entity135 . All seven @entity1 achieved symptomatic control on @entity2053 with two requiring dose titration. Of the 21 @entity1 with a negative late @entity135 , 18 achieved symptomatic control with two of these @entity1 requiring dose titration. Two @entity1 who had only partial symptom control despite dose titration achieved total symptomatic control with the addition of @entity7306 and beta-blockers. Two @entity1 with a negative late @entity135 discontinued @entity2053 due to side effects. One @entity1 had been symptomatically controlled while the other had recurrent symptoms with dose limiting side effects occurring after @entity2053 dose titration. In the 4 @entity1 with a positive late @entity135 , 2 @entity1 were symptomatically controlled, 1 @entity1 required combination therapy with a beta-blocker to achieve symptomatic control, and 1 @entity1 discontinued therapy due to side effects. Overall, 29 of 35 (83%) @entity1 continue to receive @entity2053 with symptom control. Based on intention-to-treat @entity135 results, 21 of 35 (60%) @entity1 were responders. Four @entity1 required @entity2053 dose titration and three required combination therapy with @entity2053 plus @entity7306 and/or a beta-blocker to achieve control. @entity2053 was discontinued in 6 @entity1 , 5 for side effects and 1 following a transient @entity63 attack. @entity2053 appears to be an effective therapeutic alternative in @entity1 with @entity1274 mediated @entity1163 . Based on our preliminary findings, a placebo controlled evaluation of @entity2053 in neurally mediated @entity1163 is warranted.

Efficacy and safety of @entity2053 in XXXX mediated @entity1163 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head-up tilt table test', 'HUTT'] @entity7842 :: ('MESH:D005438', 'Chemical') :: ['fludrocortisone'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity1163 :: ('MESH:D013575', 'Disease') :: ['syncope', 'presyncope'] @entity1274 :: ('MESH:D006319', 'Disease') :: ['refractory neurally'] @entity7306 :: ('MESH:D004206', 'Chemical') :: ['disopyramide'] @entity2053 :: ('MESH:D002998', 'Chemical') :: ['clonazepam', 'Clonazepam']
@entity1274 :: (MESH:D006319,Disease) :: ['refractory neurally']
